Journal Publications
Project Data Sphere's success is ultimately measured by the practice-changing scientific insights discovered by the research community. We are proud to share the following list of peer-accepted publications, and we are grateful to the data providers, research scientists, and patients that make this possible.
Author(s) | Date |
Article Title![]() |
Journal |
---|---|---|---|
Aakanksha Khandelwal, Mace Rothenberg, Sean Khozin, Amanda C Guidon, Michael Dougan, Leyre Zubiri, Laura Petrillo, Meghan E Sise, Alexandra-Chloe Villani, Douglas B Johnson, Osama Rahma and Elad Sharon |
July 2021 | Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data | Journal for ImmunoTherapy of Cancer |
Shalhout, Sophia Z.; Kaufman, Howard L.; Sullivan, Ryan J.; Lawrence, Donald; Miller, David M. |
June 2021 | Immune Checkpoint Inhibition in Marjolin Ulcer: A Case Series | Journal of Immunotherapy |
Sebastian Pölsterl, Pankaj Gupta, Lichao Wang, Sailesh Conjeti, Amin Katouzian, Nassir Navab |
July 2017 | Heterogeneous ensembles for predicting survival of metastatic, castrate-resistant prostate cancer patients | F1000 Research |
Sophia Z Shalhout, Farees Saqlain, Kayla Wright, Oladayo Akinyemi, David M Miller |
January 2022 | Generalizable EHR-R-REDCap pipeline for a national multi-institutional rare tumor patient registry | Jamia Open |
Timothe Menard, Bjorn Koneswarakantha, Donato Rolo, Yves Barmaz, Leszek Popko, Rich Bowling |
December 2019 | Follow‑Up on the Use of Machine Learning in Clinical Quality Assurance: Can We Detect Adverse Event Under‑Reporting in Oncology Trials? | Drug Safety |
Omar Abdel-Rahman, Winson Y. Cheung |
January 2018 | External validation of the prostascore model inpatients with metastatic hormone-sensitive prostate cancer recruited to the CHAARTED study | BJU International |
Xiang Yin, Pallavi S. Mishra-Kalyan, Rajeshwari Sridhara, Mark D. Stewart,Elizabeth A. Stuart, and Ruthanna C. Davi |
January 2022 | Exploring the Potential of External Control Arms created from Patient Level Data: A case study in non-small cell lung cancer | Journal of Biopharmaceutical Statistics |
Kelsey H Natsuhara, Li Zhang, Christopher A Carlos, Hala T Borno |
April 2021 | Evaluating predictors of renal injury with sorafenib in hepatocellular carcinoma: A multi-ethnic cohort study | Journal of Onco-Nephrology |
Julia Wilkerson, Kald Abdallah, Charles Hugh-Jones, Greg Curt, Mace Rothenberg, Ronit Simantov, Martin Murphy, Joseph Morrell, Joel Beetsch, Daniel J. Sargent, Howard I. Scher, Peter Lebowitz,, Richard Simon, Wilfred D. Stein, Susan E. Bates, Tito Fojo |
January 2017 | Estimation of Tumour Regression and Growth Rates During Treatment in Patients with Advanced Prostate Cancer: A Retrospective Analysis | The Lancet Oncology |
Teemu D. Laajala, Mika Murtojārvi, Arho Virkki, Tero Aittokalio |
June 2018 | ePCR: An R-package for Survival Time and Time-to-Event Prediction in Advanced Prostate Cancer, Applied to Real-World Patient Cohorts | Bioinformatics |
Steven B.Cohen, Jennifer Unangst, Feng Yu |
November 2020 | Enhancing the analytic utility of clinical trial data to inform health disparities research | Contemporary Clinical Trials Communications |
Omar Abdel-Rahman |
October 2019 | Efficacy and toxicity outcomes of elderly castrate-resistant prostate cancer patients treated with docetaxel - A pooled analysis of 3 randomized studies | Urologic Oncology: Seminars and Original Investigations |
Eric V.Li, Mohammad R.Siddiqui, Adam B.Weiner, Anna E.Prizment, Charles J.Ryan, Alicia K.Morgans |
March 2021 | Efficacy and adverse events of docetaxel for metastatic, hormone-sensitive prostate cancer among elderly men: post-hoc analysis of CHAARTED trial | Clinical Genitourinary Cancer |
Warit Ruanglertboon, Michael J. Sorich, Andrew Rowland, Ashley M. Hopkins |
May 2020 | Effect of early adverse events resulting in sorafenib dose adjustments on survival outcomes of advanced hepatocellular carcinoma patients | International Journal of Clinical Oncology |